The role of mediator mechanisms in inflammation immunopathogenesis in cardiovascular diseases and osteoporosis

Terapevticheskii Arkhiv

Volumn 81, Issue 6, 2009, Pages 92-96

  Tsurko, V V ^a   Leonenko, I L ^b   Egoror, I V ^a   Krasnoselsky, M Ya ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^b Russian State Medical University   (Russian Federation)

Author keywords

Cardiovascular diseases; Immunopathogenesis; Inflammation; Osteoporosis

Indexed keywords

AUTACOID; CYTOKINE;

CARDIOVASCULAR DISEASE; HUMAN; IMMUNOLOGY; INFLAMMATION; OSTEOPOROSIS; REVIEW;

CARDIOVASCULAR DISEASES; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; OSTEOPOROSIS;

EID: 70149111015     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. LandmesserU., Homig B., Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109 (21, suppl. 1): 27-33.
2. Ross R., Aglus L. The process of atherogenesis - cellular arid molecular interaction: from experimental animal models to humans. Diabetologia 1992; 35 (suppl. 2): 34-40.
3. Linton M. F., Fazio S. Macrophages, Inflammation, and atherosclerosis. Int. J. Obes. Relat. Metab. Disord. 2003; 27 (suppl. 3): 35-40.
4. Jovinge S., Am M. P., Misson J. Human monocytes/macrophages release TNF-alpha in response to Ox-LDL. Aiterioscter. Thromb. Vase. Biol. 1996; 16(12): 1573-1579. (Pubitemid 26427613)
5. Rosklint T., Ohlsson B. O., Wiklund O. et al. Oxysterols Induce interleukin-l beta, production In human macrophages. Eur. J. Clin. Invest. 2002; 32 (1): 35-42. (Pubitemid 36228381)
6. Liu Y, Hulttn L. M., Wiklund O. Macrophages Isolated from human atherosclerotic plaques produce IL-8. and oxysterota may have a regulatory function Tor IL-8 production. Arterioicler. Thromb. Vatc. Biol. 1997; 17 (2): 317-323. (Pubitemid 27098190)
7. Sho M., Sho E., Singh T. M. et al. Subnormal shear stress-induced intimal thickening requires medial smooth muscle cell proliferation and migration. Exp. Mol. Pathol. 2002; 72 (2): 150-160.
8. Stein O., Shibni E., Slein Y. Effect of TNF on triacylglycerol in cultured vascular smooth muscle cells. Biochim. Biophys. Acta. 1991; 1082 (1): 33-36.
9. Wohbauer G., Glide J. M., Minor L K., Rothbiat G. H. Development of the smooth muscle foam cell: uptake of macrophage lipid inclusions. Proc. Natl. Acad. Sci. USA 1986; 83: 7760-7764. (Pubitemid 17183924)
10. Avimm M. Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins. Antioxk J. Redox. Signal. 1999; 1 (4): 585-594.
11. Guyton J. R., Klemp K F. Development of the lipid-rich core in human atherosclerosis. Arterioscler. Thromb. Vase. Biol. 1996;16:4-11. (Pubitemid 26026925)
12. Mann J. M., Davies M. J. Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. Circulation 1996; 94 (5): 928-931. (Pubitemid 26292842)
13. Moreno P. R. Bernardi V. H., Lopez-Cuellar J. et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94 (12): 3090-3097. (Pubitemid 26427472)
14. Narvko T., Veda M., Haze K. et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106 (23): 2894-2900. (Pubitemid 35424738)
15. Folk E., Shah P. K., Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
16. Molioy K. J., Thompson M. M., Jones J. L. et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 2004; 110 (3): 337-343. (Pubitemid 38955503)
17. Libby P., Geng Y. J., Aikawa M. et al. Macrophages and atherosclerotic plaque stability. Curr. Opin. Lipidol. 1996; 7 (5): 330-335. (Pubitemid 26372454)
18. Sun H., Koike T., Ichikawa K. et al. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am. J. Pathol. 2005; 167 (4): 1139-1148. (Pubitemid 41416264)
19. Wilson A. M., Ryan M. C, Boyle A. J. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int. J. Cardiol. 2006; 106 (3): 291-297. (Pubitemid 41766629)
20. Kobayashi S., Inoue N., Ohashi Y. et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler. Thromb. Vase. Biol. 2003; 23 (8): 1398-1404. (Pubitemid 36994528)
21. Li J. J., Zhu C. C, Yu B. et al. The role of inflammation in coronary artery calcification. Ageing Res. Rev. 2007; 6 (4): 263-270. (Pubitemid 350130350)
22. Guzman R J. Clinical, cellular, and molecular aspects of arterial calcification. J. Vase. Surg. 2007; 45 (suppl. A): 57-63. (Pubitemid 46818872)
23. Tintut Y., Patel J., Pahmani R, Demer L L Tumor necrosis factor- a promotes in vitro caJcification of vascular cells via the camp pathway. Circulation 2000; 102: 2636-2642.
24. 2, and high intravascular pressure. Circulation 2005; 111: 2364-2372. (Pubitemid 40655331)
25. Tintut Y., Paul J., Parhami F., Demer L. L. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102: 2636-2642.
26. Cheng S. L., Shoo J. S., Charlton-Kachigian N. et al. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J. Biol. Chem. 2003; 278: 45969-45977. (Pubitemid 37432744)
27. Warner B., Mallipeddi R., Karia P. K., Lee C. H. The functional role of C-reactive protein in aortic wall calcification. Cardiology 2005; 104 (2): 57-64. (Pubitemid 41197013)
28. Jeziorska M., McCollum C, Woolley D. E. Calcification in atherosclerotic plaque of human carotid arteries: associations with mast cells and macrophages. J. Pathol. 1998; 185: 10-17. (Pubitemid 28266711)
29. Nadra I., Mason J. C, Philippidis P. et al. Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase c and map kinase pathways: a vicious cycle of inflammation and arterial calcification? Circ. Res. 2005; 96: 1248-1256. (Pubitemid 40962102)
30. Shao J. S., Cat J., Towler D. A. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler. Thromb. Vase. Biol. 2006; 26 (7): 1423-1430. (Pubitemid 44288965)
31. Rajamannan N. M., Subramaniam M., Springett M. et al. Ator-vastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002; 105: 2660-2665. (Pubitemid 34596044)
32. Otto C. M., Kuusisto J., Reichenbach D. D. et al. Characterization of the early lesion of "degenerative" valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90: 844-853. (Pubitemid 24242754)
33. Abedin M., Tintut Y., Demer L. L. Vascular calcification: mechanisms and clinical ramifications. Arterioscler. Thromb. Vase. Biol. 2004; 24: 1161-1170. (Pubitemid 38880003)
34. Wu H. D., Maurer M. S., Friedman R. A. et al. The lymphocytic infiltration in - calcific aortic stenosis predominantly consists of clonally expanded T cells. J. Immunol. 2007; 178 (8): 5329-5339. (Pubitemid 46595319)
35. Kaden J. J., Dempfle C. E., Grobholz R. et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc. Pathol. 2005; 14 (2): 80-87. (Pubitemid 40381303)
36. O'Brien K. D. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler. Thromb. Vase. Biol. 2006; 26 (8): 1721-1728. (Pubitemid 44305324)
37. Olsson M., Thyberg J., Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler. Thromb. Vase. Biol. 1999; 19: 1218-1222. (Pubitemid 29227640)
38. Katz R, Wong N. D., Kronmal R. et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Circulation 2006; 113: 2113-2119.
39. Banks L. M., Macsweeney J. E., Stevenson J. C. Effect of degenerative spinal aortic calcification on bone density measurements in postmenopausal women: links between osteoporosis and cardiovascular disease? Eur. J. Clin. Invest. 1994; 24: 813-817. (Pubitemid 24374777)
40. Schulz E., Aifai K., Liu X. et al. Aortic calcification and the nsk of osteoporosis and fractures. J. Clin. Endocrinol. 2004; 89 (9): 4246-4253. (Pubitemid 39244420)
41. Reddy J., Bilezikian J. P., Smith S. J., Mosca L. Reduced bone mineral density is associated with breast arterial calcification. J. Chn. Endocrinol. 2008; 93 (1): 208-211.
42. Skanahan C. M., Cory N. R., Metcalfe J. C. et al. High expression of genes for calcification-regulating proteins in human atherosclerotic plaque. J. Clin. Invest. 1994; 93: 2393-2402. (Pubitemid 24177151)
43. Edwards C. Hart D. J., Spector T. D. Oral statins and increased bone mineral density in postmenopausal women. Lancet 2000; 355: 2218-2219. (Pubitemid 30394332)
44. McComick R. K. Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility Altern. Med. Rev. 2007; 12 (2): 113-145.
45. Vega D., Maalouf N. M., Sakhaee K. Clinical review: the role of receptor activator of nuclear factor-kappa B (RANK)/ RAN K ligand/osteoprotegerin: clinical implications. J. Clin. Endocrinol. 2007; 92 (12): 4514-4521. (Pubitemid 350223419)
46. Li J., Sarosi I., Yan X. Q. et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 2000; 97: 1566-1571. (Pubitemid 30118482)
47. Fuller K., Murphy C, Kintein B. et al. TNFa potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002; 143: 1108-1118. (Pubitemid 34164059)
48. Rusinska A., Chlebna-Sokol D. Evaluation of interleukin-1 and -6 in the etiopathogenesis of idiopathic osteoporosis and osteopenia in children. Arch. Immunol. Ther. Exp. (Warsz.) 2005; 53 (3): 257-265. (Pubitemid 41059746)
49. Lee N., Fowler E., Mason S. et al. Tumor necrosis factor-alpha haplotype is strongly associated with bone mineral density in patients with Crohn's disease. J. Gastroenterol. Hepatol 2007; 22 (6): 913-919. (Pubitemid 46911020)
50. Ochi S., Shinohara M., Sato K. et al. Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc. Natl Acad. Sci. USA 2000; 104 (27): 11394-11399.
51. Baldini V., Mastropasaua M., Francucci C. M., D'Erasmo E. Cardiovascular disease and osteoporosis. J. Endocrinol Invest 2005; 28 (10): 69-72.
52. Mari D., Di Berardino F., Cugno M. Chronic heart failure and the immune system. Clin. Rev. Allergy Immunol. 2002; 23 (3) 325-340. (Pubitemid 35178818)
53. Yndestad A., Damas J. K., Oie E. et al. Systemic inflammation in heart failure - the whys and wherefores. Heart Fail Rev 2006; 11 (I): 83-92. (Pubitemid 43986210)
54. Irvin M., MaK S., Mann D. et al. Tissue expression and immu-noIocaJization of tumour necrosis factor-alpha in post infarction- dysfunctional myocardium. Circulation 1999; 99: 1492-1498. (Pubitemid 29140917)
55. Mann D. L. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu. Rev. Physiol. 2003; 35: 81-101. (Pubitemid 38249148)
56. Bozkurt B., Krtbbs S. B., Clubb F. J. et al. Pathophysiologicali relevant concentrations of tumor necrosis factor-alpha provokes progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97; 1382-1391. (Pubitemid 28182677)
57. Oyama J., Shimokawa H., Momii H. et al. Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardia dysfunction in dogs in vivo. J. Clin. Invest. 1998; 101 (10) 2207-2214. (Pubitemid 28244104)
58. Guranti D., Cowling A T., Varki N. et al. IL-lbeta and TNF-alpha upregulate angiotensin II type I (ATI) receptors on cardiac fibroblasts and are associated with increased ATI densit) in the post-MI heart. J. Mol. Cell. Cardiol. 2005; 38 (3): 505-515. (Pubitemid 40331941)
59. Peng J., Gurantz D., Tran V. et al. Tumor necrosis factor-alpha-induced ATI receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis Circ. Res. 2002; 91 (12): 1119-1126. (Pubitemid 36076360)
60. Candia A. M., Villacorto H. Jr., Mesquita E. T. Immune-inflammatory activation in heart failure. Arq. Bras. Cardiol. 2007; 89 (3): 183-208.
61. Silverberg D. S., Wexler D., Iaina A., Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin. Nephrol. 2006; 26 (4): 296-306. (Pubitemid 44722449)
62. Johnson T. E. Recent results: biomarkers of aging. Exp. Gerontol. 2006; 41 (12): 1243-1246. (Pubitemid 44848393)
63. Vasto S., Mocchegiani E., Candore G. et al. Inflammation, genes and zinc in ageing and age-related diseases. Biogerontol-ogy 2006; 7 (5-6): 315-327.